Bank of New York Mellon Corp Has $5.11 Million Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Bank of New York Mellon Corp boosted its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 4.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 127,093 shares of the company’s stock after buying an additional 5,448 shares during the quarter. Bank of New York Mellon Corp’s holdings in Kymera Therapeutics were worth $5,113,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of KYMR. Jennison Associates LLC boosted its stake in shares of Kymera Therapeutics by 85.8% during the 3rd quarter. Jennison Associates LLC now owns 797,681 shares of the company’s stock worth $37,754,000 after acquiring an additional 368,394 shares during the period. Wellington Management Group LLP boosted its position in Kymera Therapeutics by 7.2% during the third quarter. Wellington Management Group LLP now owns 4,618,359 shares of the company’s stock worth $218,587,000 after purchasing an additional 308,954 shares during the period. FMR LLC boosted its position in Kymera Therapeutics by 5.8% during the third quarter. FMR LLC now owns 5,109,141 shares of the company’s stock worth $241,816,000 after purchasing an additional 282,301 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Kymera Therapeutics by 212.6% in the third quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company’s stock valued at $6,649,000 after purchasing an additional 95,547 shares during the last quarter. Finally, Cinctive Capital Management LP bought a new stake in shares of Kymera Therapeutics during the 3rd quarter worth about $2,688,000.

Kymera Therapeutics Stock Up 0.3 %

NASDAQ:KYMR opened at $34.49 on Tuesday. Kymera Therapeutics, Inc. has a twelve month low of $29.07 and a twelve month high of $53.27. The stock’s 50-day simple moving average is $37.32 and its 200 day simple moving average is $42.66. The firm has a market capitalization of $2.24 billion, a PE ratio of -14.74 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The company had revenue of $7.39 million for the quarter, compared to analyst estimates of $14.81 million. On average, analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Bruce N. Jacobs sold 7,035 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $214,215.75. Following the sale, the chief financial officer now directly owns 201,886 shares in the company, valued at $6,147,428.70. This trade represents a 3.37 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ellen Chiniara sold 2,241 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $68,238.45. Following the completion of the transaction, the insider now owns 80,085 shares of the company’s stock, valued at approximately $2,438,588.25. This trade represents a 2.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 13,788 shares of company stock valued at $455,202 in the last 90 days. Corporate insiders own 15.82% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on KYMR shares. Citigroup assumed coverage on shares of Kymera Therapeutics in a report on Thursday, March 13th. They issued a “buy” rating and a $52.00 price target on the stock. BTIG Research initiated coverage on Kymera Therapeutics in a research note on Tuesday, December 10th. They set a “buy” rating and a $60.00 target price on the stock. HC Wainwright boosted their price target on Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, February 28th. BMO Capital Markets assumed coverage on Kymera Therapeutics in a research report on Friday, December 6th. They set a “market perform” rating and a $55.00 price objective on the stock. Finally, Stephens reissued an “overweight” rating and issued a $60.00 target price on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $56.36.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.